Noguchi M, Thomas M, Kitagawa H, Kinishita K, Kinami S, Takamura H, Miyazaki I, Mizukami Y
Department of Surgery (II), Kanazawa University Hospital, School of Medicine, Kanazawa University, Japan.
Breast Cancer Res Treat. 1993;26(1):67-75. doi: 10.1007/BF00682701.
This study was designed to evaluate whether DNA ploidy and/or Helix pomatia lectin (HPA) staining would be useful for predicting regional lymph node metastases and patients' prognosis in 106 patients with invasive breast cancer. The combination of DNA ploidy and HPA staining correlated better with regional lymph node metastases than DNA aneuploidy or HPA staining alone. DNA ploidy and HPA staining in combination correlated strongly with overall and disease-free survival by univariate analysis. However, the prognostic significance of DNA ploidy and HPA staining in combination was lost in multivariate analysis when regional lymph node metastases were introduced into the models. This emphasized the relationship in survival between regional lymph node metastases and the combination of DNA ploidy and HPA staining. We therefore concluded that the combination of DNA ploidy and HPA staining might provide prognostic information for breast cancer patients in whom regional lymph node dissection has not been performed.
本研究旨在评估DNA倍体和/或蜗牛凝集素(HPA)染色是否有助于预测106例浸润性乳腺癌患者的区域淋巴结转移情况及患者预后。与单独的DNA非整倍体或HPA染色相比,DNA倍体和HPA染色联合检测与区域淋巴结转移的相关性更好。单因素分析显示,DNA倍体和HPA染色联合检测与总生存率和无病生存率密切相关。然而,当将区域淋巴结转移情况纳入模型进行多因素分析时,DNA倍体和HPA染色联合检测的预后意义消失。这突出了区域淋巴结转移与DNA倍体和HPA染色联合检测在生存方面的关系。因此,我们得出结论,对于未进行区域淋巴结清扫的乳腺癌患者,DNA倍体和HPA染色联合检测可能提供预后信息。